The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A

Recruiting

Phase N/A Results N/A

Summary of Purpose

The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking. Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks. Atorvastatin is a cholesterol lowering agent. Twenty adults 18-75 years of age requiring...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 23 June 2005.

Unavailable 11 Feb 2000 Unavailable Unavailable 1 Dec 2003 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Intervention: Parallel Assignment

Contacts

  • Wei C. Lau, M.D.

    1-734-936-4280